Neo­thet­ics sheds staff, looks for sur­vival strat­e­gy in wake of tri­al fail­ure; GSK walks away from On­coMed pact

⇨ About two weeks af­ter Neo­thet­ics’ shares $NEOT nose-dived in­to pen­ny stock ter­ri­to­ry fol­low­ing the Phase II fail­ure of its aes­thet­ic fat-buster, the com­pa­ny says …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER